- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Enrollment change, Trial primary completion date: Study of Botulinum Toxin Type A (BOTOX (clinicaltrials.gov) - Feb 20, 2015 P=N/A, N=51, Active, not recruiting, Recruiting --> Active, not recruiting | N=100 --> 51 | Trial primary completion date: Sep 2015 --> Dec 2015
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: uropro: Delivery Method and Risk for Urogenital Prolapse 15-20 Years Later (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=1641, Completed, Recruiting --> Active, not recruiting | N=100 --> 51 | Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Completed | N=2200 --> 1641 | Trial primary completion date: Dec 2016 --> Feb 2014
- |||||||||| Trial completion: Validation of Korean Version of ICIQ-SF (clinicaltrials.gov) - Feb 13, 2015
P=N/A, N=134, Completed, Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Jun 2014 Active, not recruiting --> Completed
- |||||||||| apararenone (MT-3995) / Mitsubishi Tanabe
Trial completion, Enrollment change, Trial primary completion date: A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR (clinicaltrials.gov) - Feb 9, 2015 P2, N=49, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=90 --> 49 | Trial primary completion date: Jan 2015 --> Sep 2014
- |||||||||| apararenone (MT-3995) / Mitsubishi Tanabe
Trial completion, Enrollment change, Trial primary completion date: A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria (clinicaltrials.gov) - Feb 9, 2015 P2, N=67, Completed, Active, not recruiting --> Completed | N=90 --> 49 | Trial primary completion date: Jan 2015 --> Sep 2014 Active, not recruiting --> Completed | N=90 --> 67 | Trial primary completion date: Nov 2014 --> Aug 2014
- |||||||||| Trial completion: Lumbar to Sacral Ventral Nerve Re-Routing (clinicaltrials.gov) - Feb 6, 2015
P2, N=13, Completed, Active, not recruiting --> Completed | N=90 --> 67 | Trial primary completion date: Nov 2014 --> Aug 2014 Active, not recruiting --> Completed
- |||||||||| Trial primary completion date: Combined Spinal Epidural Urinary Retention (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=200, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2017
- |||||||||| Trial initiation date, Trial primary completion date: Changes in ALPP in Women With SUI Following Air Instillation (clinicaltrials.gov) - Jan 28, 2015
P1/2, N=10, Not yet recruiting, Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015 Initiation date: Apr 2014 --> Mar 2015 | Trial primary completion date: Dec 2014 --> Dec 2016
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Phase classification, Enrollment change: Rituximab to Prevent Recurrence of Proteinuria (clinicaltrials.gov) - Jan 18, 2015 P3, N=60, Recruiting, N=50 --> 8 | Recruiting --> Terminated; Terminated Phase classification: P2/3 --> P3 | N=40 --> 60
- |||||||||| NN1213 / Novo Nordisk
Trial completion: Prevent Inability To Control Urination (clinicaltrials.gov) - Jan 13, 2015 P3, N=417, Completed, Active, not recruiting --> Completed | N=612 --> 432 Recruiting --> Completed
|